Delta Capital Management LLC Has $3.16 Million Stock Holdings in Johnson & Johnson $JNJ

Delta Capital Management LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 12.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,272 shares of the company’s stock after selling 2,100 shares during the period. Johnson & Johnson accounts for approximately 1.2% of Delta Capital Management LLC’s holdings, making the stock its 22nd largest position. Delta Capital Management LLC’s holdings in Johnson & Johnson were worth $3,161,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. AustralianSuper Pty Ltd raised its position in Johnson & Johnson by 632.0% during the third quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock worth $16,536,000 after acquiring an additional 77,000 shares in the last quarter. J.W. Cole Advisors Inc. grew its position in shares of Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after acquiring an additional 2,769 shares during the period. Guinness Asset Management LTD grew its position in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after acquiring an additional 5,994 shares during the period. Treasurer of the State of North Carolina increased its stake in shares of Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after purchasing an additional 94,957 shares during the last quarter. Finally, National Pension Service raised its holdings in shares of Johnson & Johnson by 3.2% in the 3rd quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after purchasing an additional 151,707 shares during the period. Institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval / commercial launch catalyst — J&J’s new oral psoriasis drug ICOTYDE (icotrokinra) has FDA approval and encouraging 52‑week data, offering a near‑term product growth story that could boost immunology sales and investor sentiment. Will ICOTYDE’s First‑in‑Class Oral Psoriasis Launch Redefine Johnson & Johnson’s (JNJ) Immunology Narrative?
• Positive Sentiment: Analyst support — Royal Bank of Canada reiterated an “Outperform” rating, providing third‑party validation that can support institutional demand. Royal Bank Of Canada Reaffirms “Outperform” Rating for Johnson & Johnson (NYSE:JNJ)
• Positive Sentiment: Earnings momentum — Multiple writeups note J&J’s strong earnings‑surprise history and argue the company has the ingredients to beat again, a tailwind for the stock into the next report. Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Pipeline and valuation debate — Analysts and commentators are re‑examining J&J’s pipeline and dividend pedigree (Seeking Alpha, 247WallSt pieces). These arguments support a buy‑and‑hold case but leave room for differing valuations after the recent rally. Johnson & Johnson: Is The Stock Still Undervalued After The Rally? A Quantitative Approach
• Neutral Sentiment: Investor interest / trending coverage — Zacks and other outlets note higher retail/investor attention and discuss J&J as a trending defensive/dividend name amid market volatility; this increases liquidity but not necessarily directional conviction. Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Bridgewater trimming — Billionaire Ray Dalio’s Bridgewater reduced its J&J stake, which can signal cautious positioning by large funds and pressure headline sentiment despite the holding being long‑term. Johnson & Johnson (JNJ): Billionaire Ray Dalio Trims Position
• Negative Sentiment: Legal/media overhang — Continued media discussion (including Jim Cramer coverage) about prior lawsuits and the stock’s “free fall / rise” dynamic keeps a legal risk premium in place for some investors. Jim Cramer Highlights Johnson & Johnson Stock’s “Free Fall” and Rise Despite Lawsuits

Analyst Ratings Changes

JNJ has been the subject of a number of research analyst reports. Wolfe Research lifted their price target on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a report on Monday, January 5th. Stifel Nicolaus upped their price objective on Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a report on Friday, January 23rd. Finally, HSBC increased their price target on Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $236.91.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $244.20 on Thursday. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The firm’s 50-day simple moving average is $238.92 and its 200 day simple moving average is $212.08. The firm has a market cap of $588.19 billion, a price-to-earnings ratio of 22.10, a P/E/G ratio of 2.42 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. This trade represents a 45.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 30,142 shares of company stock worth $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.